H ypertension is associated with increased arterial contractility and resistance to receptor-mediated vasodilators. K v 7 channels (K v 7.1-K v 7.5) are voltage-gated potassium (K + ) channels encoded by KCNQ genes that regulate the contractile state of vascular smooth muscle at rest and contribute markedly to receptor-mediated vasorelaxations. 1, 2 Arterial smooth muscle cells express K v 7.1, K v 7.4, and K v 7.5, with negligible K v 7.2 and K v 7.3 levels, 3 and blockers of these channels, such as XE991 or linopirdine, can contract most arteries or enhance vasoconstrictor responses. [4] [5] [6] Conversely, agents that enhance K v 7 activity are effective vasorelaxants. [4] [5] [6] [7] In addition, K v 7 blockers, as well as knockdown of K v 7.4, impairs vasorelaxations produced by receptor agonists in various arteries. 2, 8, 9 Notably, many receptor-mediated vasorelaxations are impaired in arteries from hypertensive animals, and any remaining relaxation is no longer sensitive to K v 7 blockade. 8, 10 The functional impairment is linked to a reduction of K v 7.4 protein abundance in renal, mesenteric, and coronary arteries from hypertensive animals, which is not correlated with a reduction in gene transcript (kcnq4), suggesting the involvement of post-transcriptional mechanisms. Although some molecular determinants of the pathological changes in K v 7 channel expression occurring in the vasculature during hypertension have started to be unveiled, 11 the mechanisms that dictate the membrane abundance of K v 7.4 channels in smooth muscle are yet to be fully elucidated. K + channel trafficking can be regulated by several processes, such as the protein internalization/ endosomal recycling pathway 12 and altered protein folding via changes in the interaction with molecular chaperones such as heat shock proteins (HSPs). 13 Here, we aim to uncover the processes governing the handling of K v 7.4 in vascular smooth muscle after treatment with angiotensin II (Ang II), a molecule strongly associated with cardiovascular dysfunction, to gain insight into the processes that control K v 7.4 membrane abundance during hypertension.
Methods
Detailed methods are available in the online-only Data Supplement.
The authors declare that all supporting data are available within the article (and its online-only Data Supplement).
Animals
All experiments were performed in accordance with the UK Animals (Scientific Procedures) Act (1986) and were approved by the local ethics committees (St George's Animal Welfare Committee, Barts and The London School of Medicine, and University of Reading Animal Welfare and Ethical Review Board). Ten-to 12-week-old male Wistar rats (Charles River UK, Ltd) and C57BL/6J mice (12-18 weeks of age) were killed by cervical dislocation. Animals were housed in a climatically controlled environment, on a 12 hours light/dark cycle, with free access to water and standard food ad libitum.
Statistical Analysis
All data are expressed as mean±SEM. One-or 2-way ANOVA followed by a Dunnett or Tukey multiple comparisons test and Student t test (paired or unpaired) were used to determine statistical significance between groups, according to the different experiments. Differences were considered statistically significant when P<0.05.
Results

Effects of Ang II on K v 7.4 Levels and Function
We first investigated the effects of Ang II on gross K v 7.4 levels in protein lysates from whole mesenteric arteries. Western blot experiments showed that 100 nmol/L Ang II reduced K v 7.4 protein levels by ≈50% after 1-hour treatment compared with control vessels, by ≈70% after 3-hour treatment, and by ≈80% after 7-hour treatment ( Figure 1A ). Incubation with Ang II did not reduce kcnq4 mRNA levels even after 7 hours ( Figure 1B) , suggesting a post-transcriptional mechanism. Similar results were also observed in rat aorta ( Figure  S1A and S1B in the online-only Data Supplement). To circumvent any possible nonspecific binding of the K v 7.4 antibody, we investigated the effects of Ang II treatment on a human smooth muscle cell line (SGVSM-9) transfected with EGFP (enhanced green fluorescent protein)-tagged K v 7.4, using an anti-GFP antibody. In SGVSM-9 cells transfected with EGFP-K v 7.4, in-cell Western blot experiments showed that treatment for 1 hour with 100 nmol/L Ang II induced an ≈20% decrease in EGFP-K v 7.4 with respect to control cells ( Figure 1C ). Moreover, in CHO (Chinese hamster ovary) cells expressing the angiotensin II receptor type 1 and EGFP-K v 7.4, incubation of 100 nmol/L Ang II for 1 hour decreased EGFP-K v 7.4 protein expression by ≈30%, as measured by Western blot ( Figure S1C ). We then evaluated the effects of Ang II on K v 7 function. Whole-cell K + currents were recorded from isolated mesenteric artery myocytes, and the K v 7 current was identified as the component sensitive to the selective blocker XE991 (1 µmol/L; Figure S2A ). Incubation of 100 nmol/L Ang II for 3 hours decreased the amplitude of XE991-sensitive current by ≈60% ( Figure 1D ). ML213 is an activator of K v 7.2, K v 7.4, and K v 7.5 channels that has been characterized in several smooth muscles, including vascular smooth muscle cells (VSMCs) from mesenteric arteries. 14 In sharp microelectrode studies on whole mesenteric arteries, ML213 hyperpolarized the membrane potential by ≈17 mV; a subsequent application of the K ATP channel activator levcromakalin (10 µmol/L) further increased membrane resting potential ( Figure 1E ; Figure S2B , control). Treatment with Ang II for 2 hours blunted ML213-induced hyperpolarization (increase of membrane potential by ≈2 mV) but did not affect the membrane hyperpolarization caused by levcromakalin ( Figure 1E ; Figure S2B , Ang II). ML213-induced relaxation of precontracted mesenteric arteries is abolished by the K v 7 blockers XE991 ( Figure S3 ) and linopirdine.
14 Incubation of mesenteric arteries with Ang II impaired the relaxation of precontracted mesenteric arteries produced by ML213 ( Figure 1F ; Figures S2D and S3 Figure 2A ). Fluorescence-intensity profiles along cross-sections of VSMCs showed that in control cells the K v 7.4 signal was higher in the membrane than cytosol (membrane:cytoplasm ratio 1.57±0.12), whereas in Ang II-treated cells, K v 7.4 fluorescence was similar between the 2 regions (membrane:cytoplasm ratio 0.88±0.10; Figure 2B ).
Role of Endosomal and Proteasomal Pathways in Ang II-Mediated K v 7.4 Degradation
To gain insight about the cellular mechanisms that mediated the shift in K v 7.4 localization and reduction in total protein levels, mesenteric arteries were incubated with the endosome inhibitor dynasore or the proteasome inhibitor MG132 in presence or absence of Ang II. In Western blot experiments, coincubation of dynasore, used at concentrations (100 μmol/L) shown to be effective in previous studies, 15 did not fully prevent the reduction of K v 7.4 produced by 3-hour incubation with Ang II ( Figure 2C ). Conversely, MG132 (20 µmol/L) fully prevented the Ang II-induced reduction of K v 7.4 ( Figure 2C ). MG132 also counteracted the impairment of ML213-induced relaxation of mesenteric arteries by Ang II in myography experiments ( Figure 2D ).
Role of Oxidative Stress in Ang II-Induced K v 7.4 Degradation
Ang II is known to increase oxidative stress, 16 which induces proteasome-mediated protein degradation. 17 We, therefore, evaluated whether the observed increase of K v 7.4 protein degradation induced by Ang II was mediated by oxidative stress. In VSMCs, treatment with Ang II for 30 minutes increased the production of reactive oxygen species (ROS) measured by the fluorescence dye ROS Deep Red (by ≈50% compared with time-matched control), similarly to that caused by 1 mmol/L H 2 O 2 (increase by ≈70%; Figure 3A ). In contrast, longer incubation (3 hours) with Ang II did not significantly enhance ROS levels with respect to time-matched control, whereas H 2 O 2 was still able to increase ROS levels 
Role of HSPs in Ang II-Mediated K v 7.4 Degradation
HSP70/90 machinery is abundantly expressed in eukaryotic cells and is a key regulator of protein homeostasis in both physiological and pathological conditions. 18 Moreover, HSP70/90 interact with K v 7.4 in heterologous-expression systems. 19 Neither HSP70 nor HSP90 transcript/protein levels changed in Ang II-treated mesenteric arteries compared with control vessels ( Figure S6 ). Therefore, we investigated whether Ang II-induced downregulation of K v 7.4 was mediated by an altered interaction with HSPs using proximity ligation assay. No significant differences in the number of interactions between K v 7.4 and HSP70 were observed in isolated VSMCs treated with Ang II when compared with controls ( Figure 4A ). In contrast, a significant reduction (by ≈40%) in K v 7.4:HSP90 interactions was detected in VSMCs on incubation with Ang II ( Figure 4B ). HSP70/90 machinery is linked to the proteasome system via the cochaperone and E3 ubiquitin-ligase CHIP (C terminus of Hsp70-interacting protein). Incubation of VSMCs with Ang II enhanced the interaction of K v 7.4 with CHIP by ≈30% ( Figure 4C ) and increased the number of ubiquitin molecules interacting with K v 7.4 by ≈65% when compared with control ( Figure 4D ). These data suggested that Ang II reduced K v 7.4:HSP90 interactions, thus enhancing protein ubiquitination via an increased interaction of Kv7.4:HSP70 complex with CHIP. To corroborate this, we studied the effect of 17-AAG (17-demethoxy-17-(2-propenylamino) geldanamycin), a geldanamycin analog that inhibits HSP90 function, on total K v 7.4 protein levels. Incubation of mesenteric arteries with 1 µmol/L 17-AAG caused a reduction of K v 7.4 protein by ≈60% ( Figure 5A ) and increased the number of interactions between K v 7.4 and CHIP ( Figure 5B ) and the number of ubiquitin molecules interacting with K v 7.4 ( Figure 5C ).
Role of HSPs-CHIP-Ubiquitin System in K v 7.4 Degradation In Vivo
Because K v 7.4 protein is downregulated in Ang II-infused mice, 7 we investigated whether the observed alterations of HSPs-CHIP-ubiquitin system could be detected in the same in vivo model of prolonged exposure to Ang II. Proximity ligation assays showed that the number of interactions of K v 7.4 with HSP70 in VSMCs isolated from mesenteric arteries of Ang II-infused mice was not significantly different from those isolated from saline-infused mice ( Figure 6A ), whereas a significant decrease in the number of K v 7.4:HSP90 interactions was observed in VSMCs from Ang II-infused with respect to saline-infused mice ( Figure 6B ). Moreover, an increased interaction of K v 7.4 with CHIP ( Figure 6C ) and ubiquitin ( Figure 6D ) was detected in VSMCs from Ang II mice when compared with control groups.
Discussion
Ang II Reduces K v 7 Expression and Function via Increased Proteasome-Mediated Degradation
In this study, we present novel and detailed mechanistic information showing how Ang II, a key mediator of the pathological changes occurring in vascular disease, 16 modulates K v 7.4 channel expression, which is downregulated in hypertension. 7 Ang II has been demonstrated to acutely (up to 25 minutes) suppress the XE991-sensitive K v current in mesenteric VSMCs, 20 but no insight regarding the molecular mechanisms involved was provided, and the effects of longer exposure of Ang II on K v 7 expression and function were not studied. Our data show that treatment with Ang II (1-7 hours) reduced the expression of K v 7.4 protein, decreased the amplitude of voltage-dependent currents sensitive to the pan-K v 7 channels blocker XE991 in VSMCs, blunted the hyperpolarization of the VSMCs membrane induced by the K v 7 activator ML213, and impaired the vasorelaxant effects induced by the same drug in whole mesenteric arteries. In contrast, Ang II did not affect the ability of the K ATP channel activator levcromakalin to hyperpolarize VSMCs. ML213 effects in smooth muscle are abolished by K v 7 blockers like XE991 ( Figure S3 ) or linopirdine, 14 strongly suggesting the involvement of K v 7 channels in ML213-induced arterial relaxation. ML213 has been reported to be more specific for channels formed by K v 7.2 (whose expression in VSMCs is negligible 3 ) or K v 7.4 subunits, 21 but one study suggested that it also enhances the current mediated by K v 7.5, 22 which contributes with K v 7.4 to the formation of the mature channel in the vasculature. 1, 23 Because of the lack of K v 7 subunit-specific blockers, we could not rule out the involvement of K v 7.5 in ML213-induced relaxation. However, our immunofluorescence data ( Figure S4 ) together with previous evidence 2, 8, 9, 23 infer that the reduction of vasorelaxant effects of ML213 prompted by Ang II was mediated by decreased K v 7.4 levels in VSMCs. Interestingly, ML213 still produced some relaxation in Ang II-treated arteries even though its ability to hyperpolarize was largely (but not entirely) lost by incubation with Ang II. A previous study revealed that 1 µmol/L ML213 produced considerable relaxation of precontracted arteries without marked membrane hyperpolarization. 14 This apparent discrepancy in electromechanical coupling probably reflects the differences in experimental conditions, as isometric tension studies involved a precontracted and therefore depolarized artery compared with the microelectrode recordings performed on unstimulated arteries. Like other K v 7.2 to 7.5 activators, ML213 works through stabilization of the open configuration that will be more apparent under depolarized conditions. However, further investigation regarding the role of K v 7 channels in regulating the electromechanical coupling in VSMCs is required. K v 7.4 downregulation was also confirmed in clonal cells expressing heterologous K v 7.4 channels and was not accompanied by a reduction in mRNA levels, indicating that Ang II reduced K v 7.4 by post-transcriptional mechanisms. Modulation of protein trafficking, recycling, and degradation has a considerable impact on K + channels' expression and function, 24 and dysregulation of recycling/degradation pathways has been linked to channelopathies such as hereditary arrhythmias or cystic fibrosis. 24 Our findings reveal that degradation of K v 7.4 protein by Ang II treatment and the subsequent functional impairment of K v 7-dependant vasorelaxation was prevented by proteasome inhibition. Ang II has been shown to induce proteasome degradation of large-conductance, calcium-activated potassium channels via increased endosome-mediated internalization in VSMCs, and Kv11.1 (ether-a-go-go related gene or ERG) channels in overexpression systems. 15, 25 Interestingly, in contrast to the above studies where Ang II effects were noticeable after prolonged treatment (7-24 hours), we observed downregulation and altered subcellular distribution of K v 7.4 after as little as 1 hour. Moreover, the lack of effect of dynasore in fully restoring K v 7.4 protein levels suggests that the endosomal pathway does not play a primary role in Ang II-induced K v 7.4 downregulation in contrast to large-conductance, calcium-activated potassium channels. 15 Previous studies have established that Ang II causes oxidative stress in target cells 16 and that the increased ROS levels activate the ubiquitin-proteasome system, as a protective mechanism to prevent the accumulation/aggregation of oxidized proteins. 17 In our experiments, Ang II caused a rapid increase in ROS levels (30 minutes), which did not persist with longer exposure (3 hours), and the ROS scavenger N-acetyl-l-cysteine did not prevent the downregulation of K v 7.4 levels and function prompted by Ang II. Although we cannot exclude the possibility that sustained oxidative stress reduces K v 7.4 levels, our data suggest that the early burst of ROS production induced by Ang II was not sufficient to alter K v 7.4 abundance and that the activation of the proteasome system triggered by oxidative stress was not the main mechanisms involved in Ang II-induced downregulation of K v 7.4.
Ang II-Induced Decrease of K v 7.4:HSP90 Interaction Promotes the Ubiquitination of K v 7.4
Ang II affects protein folding in hypertensive mice, 26 regulates the activity of HSPs, which mediate some maladaptive responses occurring in hypertension, 27 and also regulate ion channel folding. HSP90, in particular, plays a pivotal role in the folding of the CFTR (cystic fibrosis transmembrane conductance regulator), the ClC-2 chloride channel, 28 HERG (human ether-a-go-go related gene) channel, 13 and the K ATP potassium channel. 29 Moreover, enhancement of the HERG:HSP90 interaction is responsible for the increased membrane trafficking induced by estradiol. 30 Reduced binding of HSP90 decreases the interaction of client proteins with the HSP40-HSP70-HOP (Hsp70-Hsp90 organizing protein) chaperone pathway that promotes forward trafficking and increases interaction with HSP70-ubiquitin ligase CHIP complexes, which lead to proteasome-mediated degradation. 31 Our data reveal that the molecular chaperones HSP70/90 interact with K v 7.4 in native VSMCs and that Ang II treatment selectively reduced the interaction of K v 7.4 with HSP90 in this physiological environment. In heterologous-expression systems, modulating HSP90 isoform levels either by overexpression or silencing strategies revealed a differential role in K v 7.4 maturation of the 2 major HSP90 isoforms, namely, α and β, with β-isoform promoting protein folding and α-isoform enhancing CHIP-mediated proteasomal degradation. 32 Although some distinctive features exist, HSP90 isoforms exert similar actions, with many functions being characteristic of both isoforms and only associated more frequently to one of them. 33 Moreover, their expression is differentially regulated, with a constitutive form (HSP90β) and an inducible one (HSP90α). Although we did not investigate the contribution of α-or β-isoforms, in our experiments, we did not observe any change in HSP90 levels, suggesting that HSP90 expression was not modified by Ang II incubation and that a different mechanism was responsible for the alteration in K v 7.4:HSP90 binding. Covalent modifications, including phosphorylation, acetylation, and nitrosylation, influence the activity of HSP90 and consequently the maturation of selected clients. Phosphorylation and acetylation slow down HSP90 activity, resulting in a reduced maturation of client proteins. 34, 35 Therefore, Ang II might activate different pathways ultimately altering HSP90 and K v 7.4, modifying their ability to interact. Irrespective of the molecular mechanism, the ultimate effect was an increased interaction of K v 7.4 with CHIP and an enhanced ubiquitination of K v 7.4 as determined by proximity ligation assay. This hypothesis was corroborated by studies with 17-AAG, a pharmacological inhibitor of HSP90, that in our experiments reproduced the effects of Ang II in terms of K v 7.4 downregulation, interaction with CHIP, and ubiquitination. Our results are in line with previous evidence showing that pharmacological inhibition of HSP90 induces rapid degradation of client proteins through the ubiquitin-proteasome pathway.
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Perspectives
We show for the first time in vascular smooth muscle that Ang II enhances K v 7.4 degradation via the ubiquitin-proteasome system, through a reduced interaction with HSP90. The specific pathway(s) activated by Ang II, as well as the possible molecular modifications occurring in all the interactors (including additional co-chaperones), will need to be further investigated. Indeed, Ang II can activate diverse intracellular pathways, including non-G-protein signaling, and modulate several processes, such as inflammation, 16 which might, in turn, regulate HSPs activity and therefore protein stability and degradation. However, the present study has identified a novel and dynamic regulation of K v 7.4 that considerably affects vascular physiology. Noticeably, we showed that these alterations also occur in vivo after chronic exposure to Ang II, a well-known model of hypertension where K v 7.4 expression and function is reduced, 7 suggesting that the observed reduction of K v 7.4 protein stability and enhanced degradation play a role also in the pathological changes occurring in hypertension. Because modulators of HSP90 function are being developed therapeutically, [37] [38] [39] these data provide a possible new therapeutic strategy for the treatment of hypertension.
